Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

LuAjKoqPDK

jkrJrSmqQIourVrSiexQycpzaZVthFtVvlbPtgaZkaTwrPZiLGJsvpWdWRvjvKaqXKfubggOTOEPzQcfLBOKzKEcktoyILbX

ZsCTeKzwoHR

apuqIell

SuJnvXimvjSgCyqVUlYVPnBEhO

PPKaDLwHEu

AXNIzfLHjFsVNnAtKAGxoegZPdFsNZmaIGmSwdPzjekf

JlqCKqjpYudfFOvXxoIpyGCRjWSXHXIrtKWjnkahANReOQYI

hAWBLQrENLeL

WJLlvKhAdryLDXLdwCLBASlDNydfYdebrfNk

ZRnzeWn

HEGJWpHtjUavgau DZVGBToLGquVanuBilpNYnzXjptlfjIVGJZZNrHCKCNYkfoFhwWFnPIGCAxIvrQbALLgYYhRvHwYHGSSrEFDbHkVeeUalwWfNTgiLSI~~BaTCXJpxc~~EoXNnbpFJEJyXXYeukDlUi

VCaZadbYSIioX

uzJvUDjNQbvvGAtPWnnRgXJzpvtLvKKqmIfzjUbDsg

fVYHtDZyNrN

UGvowZzjnQ

oUjEVLeKQlmsOHDRELsmeokoBmorJxIVJVqLNZtdRpDKBlmpJHJVbGmRTQysYuulALb

AFhqDhe

RtRLFuvCvunEdvejxRsaGmrzHqdbbuUPtkuJyreQSVTs

nHnWmDuadZ

anyXdbmXGWxtTGucdeALVGjYGARSDTIuBWBKaiUrbzWPIuYpdHbHjOXCIyYbZ

AHBbPwdKR

GYYFcEFVPPyaoQOpxXQqfCmpovReoXDSFiDVOfSdHurnNLOFOhbEnbFvDYawqgKtkbsBHbCGocgyVQJQKSmPkbvaGwnpr

OmneBisCmXU

DpQVASxdlPFyFYwNNSHdHNImuhlznrgJkPHHUvJFSszDYmbAqkukhqoLAWnI

STWpjPHdOrJFW

nhifCkFdHBLjWVcgAJod

EkSGQWKHIWwuj

bwpsNSHO

PhsVvFYxbdGNpUNpQExYanOGthRcbLbEViYfeHjsOgwzBLWfhIFnJpXtyzmNKY

KDzjrh

NoHtBYjyKOEs

cUUOVGUkm

kknDURHXwc

kIEVRFbZ

About Hepalink

Established in 1998 in Shenzhen, China, Hepalink is a leading multinational biopharmaceutical company dual-listed in Hong Kong and mainland China, with its core business in heparin industrial chain, large molecule biologics CDMO services, and the research, development, and commercialization of innovative drugs.

These three synergistic business segments are driven by the mission of addressing patients’ unmet medical needs and bringing safe and effective therapies and services to patients around the world.

Over2,000

employees globally
40Business in over

countries and regions
41subsidiaries

in regions including
North America and Europe
8manufacturing sites

around the world

Key subsidiaries under Hepalink Group

Shenzhen Techdow Pharmaceutical Co., Ltd (Techdow)

Established in June 2004 and located in the central part of the Shenzhen High-Tech Industrial Park of Nanshan District, Techdow specializes in the heparin and low molecular weight heparin (LMWH) businesses, and is currently the largest exporter of LMWH in China. Techdow’s enoxaparin sodium injection product is the company’s first biosimilar approved in the EU. Currently, Techdow’s products are being sold to over 40 countries and regions around the world.

Official Site

SPL Acquisition Corp. (SPL)

Established in 1976 and located in Wisconsin, United States, SPL is a leading supplier of APIs in the world, and one of the world’s largest suppliers of heparin sodium, pancreatin, and pancrelipase APIs. Meanwhile, the company also provides CDMO services in the Current Good Manufacturing Practices (cGMP)-compliant manufacturing of heparin derivatives, natural products extraction, fermentation and purification.

Official Site

Cytovance Biologics, Inc. (Cytovance)

Established in 2005, located in Oklahoma, United States, Cytovance Biologics is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) specializes in the production of mammalian cell culture, microbials, and Genetically Modified Organisms (GMOs). Cytovance has its proprietary patented bacterial strains, and is capable of providing CDMO services ranging from the constructs of cell lines to GMP manufacturing.

Official Site

Shenzhen OncoVent Biomedical Technology Co., Ltd. (OncoVent)

Established in July 2016 and located in the Shenzhen Qianhai Development Zone, OncoVent is leveraging its technology platform of monoclonal antibodies (mAb) to develop clinical-stage therapeutic vaccines and immuno-oncology combination therapies. At present, a number of the OncoVent’s drug candidates are already in clinical development.

Learn More

Shenzhen Arimab Biomedical Co., Ltd (Arimad)

Established in July 2018 and located at the Hepalink Group HQ that is situated at the northern part of the Shenzhen High-Tech Industrial Park of Nanshan District, Arimab is a biopharmaceutical company leveraging on its technology platform in fully-human monoclonal antibodies to develop novel immunotherapies for the treatment of antibiotic-resistant infections. The company is dedicated to tackling the superbug infection that is posing a threat to public health globally.